Title |
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, August 2020
|
DOI | 10.1186/s13063-020-04632-4 |
Pubmed ID | |
Authors |
Miguel Rodríguez-Rubio, Juan Carlos Figueira, Darío Acuña-Castroviejo, Alberto M. Borobia, Germaine Escames, Pedro de la Oliva |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 21% |
Brazil | 1 | 7% |
Uruguay | 1 | 7% |
United Kingdom | 1 | 7% |
India | 1 | 7% |
Spain | 1 | 7% |
Unknown | 6 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 43% |
Scientists | 5 | 36% |
Practitioners (doctors, other healthcare professionals) | 2 | 14% |
Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 301 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 301 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 41 | 14% |
Researcher | 35 | 12% |
Student > Master | 29 | 10% |
Other | 20 | 7% |
Student > Ph. D. Student | 13 | 4% |
Other | 51 | 17% |
Unknown | 112 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 82 | 27% |
Nursing and Health Professions | 32 | 11% |
Biochemistry, Genetics and Molecular Biology | 10 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 3% |
Psychology | 8 | 3% |
Other | 37 | 12% |
Unknown | 122 | 41% |